Aberrant expression of sLe x and sLe a as candidate prognostic factors for feline mammary gland tumour

Abstract

Expression of the carbohydrate antigens sialyl Lewis x (sLe^x) and a (sLe^a) was evaluated in feline mammary gland tumours (FMGT). Immunohistochemical analysis of tissues from 21 FMGT patients and 11 healthy cats revealed significantly higher sLe^x and sLe^a antigen expression in adenocarcinoma tissues compared with that of normal mammary tissues (P <0.01). Serum concentration of sLe^x was evaluated using an enzyme-linked immunosorbent assay and was significantly higher in the 11 FMGT patients (4.71 ± 10.1 U/ml) than the 22 patients with other disease (2.69 ± 1.59 U/ml) (P = 0.03) and the 22 healthy cats (3.71 ± 1.10 U/ml), although the latter difference was not significant. Although the number of cases examined in this study was small, our findings suggest that aberrant expression of sLe antigens may be induced by tumourigenesis in FMGT and that sLe antigens are potential prognostic tumour markers for FMGT.

Introduction

Feline mammary gland tumours (FMGT) are the third most common type of tumour found in cats following haematopoietic neoplasms and skin tumours.^1–4 Approximately 90% of FMGT are histologically malignant, and show rapid progression and metastasis at an early stage of disease.^1–4 Usually classified as adenocarcinomas, FMGT often invade locally and easily metastasise to regional lymph nodes, the lung and pleura.^1–4 Conventional treatments, such as surgery, chemotherapy and radiation therapy, may not confer adequate benefits in advanced cases.⁵ Several prognostic indicators have been reported, including tumour size, mitotic count, clinical stage and surgical procedure.^4–7 Several molecular markers, such as human epidermal growth factor receptor-2, cyclooxygenase-2 and vascular endothelial growth factor, have been reported to be associated with clinical outcome in immunohistochemical analysis.^8–11

Tumour metastasis is a multistep process that involves detachment of cells from the primary mass, invasion of blood or lymph vessels, interaction with the endothelium, extravasation at distant sites and formation of new tumour foci.¹² Various factors are required for this process, including cell adhesion molecules, matrix metalloproteinases, angiogenic factors and chemokines.^12,13 Several adhesion molecules have been identified as playing an important role in the extravasation cascade,¹² and it is now widely believed that adhesion between E-selectin and its ligands, sialyl Lewis x (sLe^x) and sialyl Lewis a (sLe^a) initiates a significant step in tumour extravasation.¹⁴ The carbohydrate ligands sLe^x and sLe^a are known to adhere to E-selectin, a member of one of the selectin families whose expression is induced on vascular endothelial cells by inflammatory cytokines.¹⁴ These carbohydrate ligands are expressed on monocytes, granulocytes, natural killer cells and activated lymphocytes, and their adhesion to E-selectin is the first step of interaction between the vascular endothelium and leukocytes during the inflammatory process. It has become apparent that cancer cells mimic the behaviour of immune cells to spread throughout the body and form metastatic foci.^13–15 By exposing sLe antigens on their cell surface, disseminated circulating cancer cells may extravasate from the bloodstream into the peripheral tissues, in whose vessels selectins are highly expressed (see Figure 2 in Kannagi et al¹⁵). Malignant transformation is frequently associated with this drastic alteration in the surface expression of carbohydrate determinants.^16,17

Aberrant cell surface glycosylation is a common phenotypic change that occurs during carcinogenesis,¹⁶ and sLe^x and sLe^a determinants are well-known cancer-associated glycans.^16,17 These antigens are tetrasaccharides derived from type 2 (β-Gal-(1-4)-GlcNAc) and type 1 (β-Gal-(1-3)-GlcNAc) disaccharide sequences with fucose and sialic acid substitutions, respectively.¹⁸ In humans, expression of sLe^x and sLe^a is reported to be markedly increased in carcinoma cells.^15,18 The sLe^x determinant was found to be strongly involved in the adhesion of breast, ovarian and pulmonary cancer cells.^14,19 In breast carcinoma, the presence of sLe^x also correlates with poor prognosis²⁰ and serum sLe^x antigen levels are increased in patients with advanced breast cancers.²¹ In contrast, sLe^a antigen levels are high in cancers of the digestive organs.^22,23 There are some reports of sLe antigens expression in mammary gland tumours of small animals; however, information regarding sLe antigens is still limited.^24–26

The purpose of this study was to evaluate whether or not sLe antigen expression correlates with histopathological features of malignancy and clinical outcomes of FMGTs. To achieve this goal, sLe^x and sLe^a tissue expression, and serum sLe^x levels were examined in spontaneous FMGT patients to evaluate the relationship between sLe antigen expression and the clinicopathological features of FMGT.

Materials and methods

This study was approved by the Ethics Committee of Animal Use and Care Committee of the Graduate School of Agricultural and Life Sciences, The University of Tokyo.

Tissue samples

FMGT tissues were obtained from 21 patients who underwent unilateral mastectomy at the University of Tokyo Veterinary Medical Center between April 2006 and November 2010. Normal mammary gland tissues were obtained from 11 healthy cats. Age, breed, body weight, history of spaying, histopathological diagnosis, tumour size and site, regional lymph node involvement and distant metastasis by thoracic X-ray findings at time of referral to our hospital were obtained from medical records. In our hospital, regional lymph node involvement was examined by palpation. If palpable, we performed cytology to confirm nodal status. Clinical outcome was confirmed by a telephone interview with the client or referring practitioner. Abdominal ultrasound or post-mortem examinations were not performed. Tumour size was calculated based on the maximum diameter of the largest mass from the patient. Distant metastasis was confirmed by thoracic radiography in all cases. The World Health Organization clinical stage was used for the classification of FMGT staging,⁴ and survival time was defined as the time from surgery to death.

Serum samples

Serum samples were collected from 55 cats between January 2009 and October 2010, of which 11 had FMGT, 22 had been referred to the Veterinary Medical Center with other diseases and the remaining 22 were healthy cats. Other diseases included tumours other than FMGT, inflammatory diseases, bone fracture, etc. After blood sampling, serum was separated and stored at –20°C until analysis. The medical records of the patients with other diseases were also reviewed.

Antibodies

Mouse monoclonal anti-human sLe^x (clone CSLEX1, dilution rate 1:500) was obtained from BD Biosciences and mouse monoclonal anti-human sLe^a (clone 1H4, dilution rate 1: 100) was obtained from Seikagaku.

Immunohistochemistry

Expression and localisation of sLe^x and sLe^a on the tissue samples were analysed by immunohistochemistry. Tissues were fixed in 10% neutral-buffered formalin for 2–3 days and embedded in paraffin. A series of 2–4 μm-thick sections were cut for immunohistology and histological diagnosis by light microscopy. Formalin-fixed paraffin-embedded sections were deparaffinised in xylene and rehydrated through a series of graded ethanols followed by distilled water. Antigen retrieval was performed for sLe^a by autoclaving slides for 10 mins at 121°C in citrate buffer (pH 6.0); examination of sLe^x did not require this process. Immunohistochemical procedures were performed using a DAKO ENVISION+kit/HRP (DAB) (DAKO Japan). Sections were washed in phosphate-buffered saline and the endogenous peroxidase activity was abolished by treatment with 0.3% hydrogen peroxide in Tris-buffered saline containing 0.1% Tween 20 (TBS-T). The sections were then incubated with 5% normal goat serum in TBS-T for 1 h, followed by the primary antibody (sLe^x and sLe^a at a dilution of 1:1000) for 2 h at 37°C. Sections of canine normal oesophagus and canine mammary gland adenocarcinoma were used as positive controls for sLe^x and sLe^a respectively. Sections that stained only the secondary antibody were evaluated as negative controls. After washing with TBS-T, samples were treated with the polymer solution containing the horseradish peroxidase (HRP)-conjugated antibody against mouse IgG at 37°C for 30 mins. Samples were then washed again and visualised with the DAB/hydrogen peroxide solution (DAKO). For light microscopy, sections were stained with haematoxylin and eosin. For the evaluation of immunohistochemistry, five photos were taken randomly at 200× magnification for each slide. The total cell area and the sLe^x-positive or sLe^a-positive cell area were measured using ImageJ software. Briefly, we distinguished the positive epithelial cells and drew the positive cell area manually. Also, the tumoural cell area was drawn manually. The positive ratio (positive cell area/total cell area) was then calculated, and the mean of five positive ratios was used as the positive ratio for each slide.

Measurement of serum sLe^x concentration

Serum concentrations of sLe^x were measured by a sandwich enzyme immunoassay (EIA) using the N-test EIA plate CSLEX kit (Nittobo Medical). Briefly, serum samples were reacted with the first anti-sLe^x monoclonal antibody (clone: CSLEX1) immobilised in wells of the plate at 37°C for 2 h. Next, the second anti-sLe^x monoclonal antibody labelled with HRP was added and incubated for 2 h at 37°C. Bound, HRP-labelled antibodies reacted with the substrate tetramethylbenzidine for 10 mins at room temperature, and optical densities were measured at 450 nm with a microplate reader (Model 680 Microplate Reader; Bio-Rad). Concentrations of sLe^x were expressed as U/ml.

Statistical analysis

Statistical analyses of immunohistochemistry data were carried out with the Kruskal–Wallis H-test and the Mann–Whitney U-test with Bonferroni’s correction. Comparison of variables among groups according to the degree of sLe expression was carried out with the X² test or Kruskal–Wallis H-test. Statistical analyses of serum sLe^x concentrations were carried out with the Kruskal–Wallis H-test. Patient survival was analysed using the Kaplan–Meier method and evaluated by the log rank test. Dead cats with lung metastasis and dyspnoea were defined as death. The cats that died from other disease or unknown causes were censored. The cats that survived at the investigation were also censored. All these analyses were performed using Excel and Stat View, and a probability of less than 5% (P <0.05) was considered significant.

Results

Clinicopathological features of patients with FMGT

The clinicopathological features of the 21 FMGT patients are listed in Table 1. Clinical stages were determined based on the maximum size of the tumour in each patient, status of lymph node and distant metastasis at time of referral. All cats were female, and the mean age at surgery was 11.8 years (range 7.8–15.3 years). Of these 21 cats, two were mixed breed, 14 were Japanese domestic cats, and the remaining five were Himalayan, Abyssinian, Persian, Russian Blue and Scottish Fold. After surgery resection, only three cats received chemotherapy, including carboplatin and doxorubicin, vincristine, adriamycin, and cyclophosphamide (VAC) protocol and metronomic chemotherapy (combination of cyclophosphamide and piroxicam), respectively. These cats were excluded from the data of clinical outcome. Ten of these cats developed distant metastasis. Normal cats were all intact female and Japanese domestic cats. The mean age at tissue collection was 3.7 years (range 1.4–8.8 years) and the mean body weight was 4.3 kg (range 2.7–5.3 kg) when they were euthanased for other experiments.

Table 1

Clinicopathological features of 21 feline mammary gland tumour (FMGT) patients

		Adenocarcinoma(n = 19)	Adenoma(n = 2)
Age (years)	Mean ± SD	11.6 ± 2.0	13.3 ± 1.3
Ovarian status	Intact	7	1
	Spayed	12	1
Weight (kg)	Mean ± SD	4.0 ± 0.9	2.8 ± 0.4
Clinical stage	I	6	2
	II	5	0
	III	6	0
	IV	2	0
Tumour size (cm)	Mean ± SD	2.7 ± 1.6	0.7 ± 0.2
	<2	6	2
	2–3	7	0
	>3	6	0
Regional lymph node	Positive	3	0
involvement*	Negative	12	2
Distant metastasis*	Positive	9	1**
	Negative	6	1
Outcome*	Alive	4	0
	Dead (FMGT)	8	1**
	Dead (unknown cause)	3	0
	Dead (other disease)	0	1
	Lost to follow- up	1	0

At the end of study period (excluding the three cats that received chemotherapy)

This cat died owing to the recurrence and metastasis of adenocarcinoma

Expression of sLe^x and sLe^a in FMGT tissues

We obtained 53 FMGT tissue specimens from 21 patients. Histological diagnoses were as follows: 43 adenocarcinomas, five adenomas, three mammary hyperplasias, and two metastatic tissue specimens of the pleura and peritoneum. Typical immunohistochemical findings of sLe antigens on FMGT tissues are depicted in Figure 1. sLe^x expression was expressed on the cell membrane and in the cytoplasm, while sLe^a was expressed diffusely throughout the cell.

Figure 1

Immunohistochemical analysis of (a) sLex and (b) sLea on tissues of feline mammary gland tumour FMGT patients. - = low (expression level under 4.9%); + = moderate (expression level between 0.5% and 29.9%); ++ = high (expression level >30%)

Expression levels were defined as follows: low expression (-) was defined as <4.9% of the positive rate; moderate expression (+) was defined as between 5% and 29.9%; and high expression (++) was defined as >30%. The expression levels of sLe^x and sLe^a on the tissues of the FMGT patients are summarised according to this classification in Table 2. Among the 43 adenocarcinoma tissue specimens, 35 (81.3%) showed low (n = 17, 39.5%) -to-moderate (n = 18, 41.9%) sLe^x antigen expression levels, while eight (18.6%) showed high expression (Table 2). Similarly, sLe^a epression levels on adenocarcinomas were low-to-moderate in 22 (51.1%) tissues, but high in 21 (48.8%) tissues (Table 2). Among the five adenoma tissues examined, only one demonstrated positive staining (+) of sLe^x, while the remaining four adenoma, all three hyperplasia and 11 normal mammary gland tissue specimens showed low sLe^x and sLe^a expression. In the two metastatic tissue specimens, sLe^x and sLe^a expression was low in one, whereas the other showed high expression of both antigens.

Table 2

sLe^x and sLe^a expression on different histological tissue types

	Number	(-)	(+)	(++)
sLe^x
Adenocarcinoma	43	17 (39.5%)	18 (41.9%)	8 (18.6%)
Adenoma	5	4 (80%)	1 (20%)	0
Hyperplasia	3	2 (66.7%)	1 (33.3%)	0
Normal mammary gland	11	11 (100%)	0	0
Metastasis lesion	2	1 (50%)	0	1 (50%)
sLe^a
Adenocarcinoma	43	15 (34.9%)	7 (16.3%)	21 (48.8%)
Adenoma	5	2 (40%)	2 (40%)	1 (20%)
Hyperplasia	3	3 (100%)	0	0
Normal mammary gland	11	10 (90.9%)	1 (9.1%)	0
Metastasis lesion	2	1 (50%)	0	1 (50%)

The mean values of the positive ratios of sLe^x and sLe^a expression in malignant (adenocarcinoma), benign (adenoma and hyperplasia) and normal mammary tissues are shown in Figure 2. Using the Mann–Whitney U-test with Bonferroni’s correction, significant differences were observed in sLe antigen expression between the adenocarcinoma and normal mammary gland tissues (P <0.01). In contrast, no statistically significant differences were observed between the adenocarcinoma and benign tissues, although the benign tissues tended to show lower expressions than adenocarcinoma for both sLe antigens.

Figure 2

Positive ratios of (a) sLex and (b) sLea expression from adenocarcinoma, benign and normal mammary gland tissues. The value is depicted as data plot and mean (**P <0.01)

Relationship between expression of sLe antigens and clinicopathological features

The correlation of sLe^x and sLe^a expression to clinicopathological features in FMGT was examined, and the results are shown in Table 3. No significant differences were found among groups exhibiting either low (-), moderate (+) or high (++) sLe expression and each of the clinicopathological variables.

Table 3

Relationship between sLe^x and sLe^a expression, and clinicopathological features in feline mammary gland tumour (FMGT) patients

Clinicopathological features	sLe^x expression			P
	(-)	(+)	(++)
Age (years)				NS
Mean ± SD	11.7 ± 2.4	11.7 ± 1.4	12.2 ± 2.9
Ovarian status				NS
Intact	1	6	1
Spayed	5	4	4
Weight (kg)				NS
Mean ± SD	4.4 ± 1.3	3.6 ± 0.9	3.8 ± 0.1
Clinical stage				NS
I	1	4	3
II	2	2	1
III	3	3	0
IV	0	1	1
Maximum tumour size (cm)
Mean ± SD	2.6 ± 1.5	2.9 ± 1.5	1.4 ± 0.5	NS
<2	1	3	4	NS
2–3	3	4	1
>3	2	3	0
Regional lymph node involvement*				NS
Positive	1	1	0
Negative	4	8	4
Distant metastasis*				NS
Positive	2	6	2
Negative	3	3	2
Clinicopathological features	sLe^a expression			P
	(-)	(+)	(++)
Age (years)
Mean ± SD	12.7 ± 1.6	11.4 ± 4.1	11.7 ± 1.9	NS
Ovarian status Intact	1	0	7	NS
Spayed	2	2	9
Weight (kg) Mean ± SD	5.5 ± 1.1	3.3 ± 0.5	3.6 ± 0.7	NS
Clinical stage				NS
I	0	1	7
II	2	0	3
III	1	0	5
IV	0	1	1
Maximum tumour size (cm)				NS
Mean ± SD	3.5 ± 1.3	1.8 ± 1.8	2.4 ± 1.4
<2	0	1	7	NS
2–3	2	1	5
>3	1	0	4
Regional lymph node involvement*				NS
Positive	0	1	1
Negative	3	1	12
Distant metastasis*				NS
Positive	2	1	7
Negative	1	2	6

NS = not significant

At the end of study period (excluding the three cats that received chemotherapy)

Long-term follow-up was performed on 20 patients, and one patient was lost to follow-up. Fourteen cats died owing to FMGT, one cat died from other disease and one cat died from an unknown cause. A follow-up survey could not be performed for in one cat, and four cats are still alive without any metastasis. Among the 14 patients that died of FMGT, 10 showed high sLe^a expression. According to the results of Kaplan–Meier curves and log rank test, however, there was no significant difference based on the expression level of both sLe antigens (sLe^x: P = 0.47; sLe^a: P = 0.19).

sLe^x concentrations in serum of FMGT patients

The serum sLe^x concentrations of mammary adenocarcinoma patients, patients with other disease and normal cats are shown in Figure 3. The normal cat population was demographically similar to the normal population used for tissue collection. Mean values (± SD) were 4.71 (± 10.1) (range 0.636–46.733), 2.69 (± 1.59) (range 0.318–6.013) and 3.71 (± 1.10) (range 0–5.37) U/ml, respectively. Significant differences were found in these values between mammary adenocarcinoma patients and those with other diseases (P = 0.03). In contrast, statistically there was no difference between mammary adenocarcinoma patients and normal cats; however, normal cats did exhibit a tendency toward lower sLe^x concentrations more than mammary adenocarcinoma patients did.

Figure 3

Serum sLex expression in feline mammary gland tumour patients and others. The value is depicted as data plot and mean (*P <0.05)

Discussion

In this study, we evaluated the expressions of sLe antigens in FMGT tissue samples and normal mammary gland tissues from healthy cats. Adenocarcinomas showed significantly higher sLe antigen expression than normal mammary gland tissues did. Most adenocarcinoma tissues also showed higher sLe^x expression than adenoma tissues, but the difference was not significant. The carbohydrate antigen, sLe^x, was considered to be expressed with malignant alteration, which is in agreement with previous reports.^18,24,26,27 Similar to sLe^x, sLe^a showed significantly higher expression levels in adenocarcinoma than in normal tissues. Although the difference was not significant, adenocarcinoma tissues also showed higher sLe^a expression than adenoma tissues. This result is similar to that of previous reports on human breast cancers,^18,27 but differs from previous reports on canine mammary gland tumours (MGT).²⁵ In this study the mean age of normal cats was younger than that of MGT patients; this difference was considered a limitation of the study. Although sLe^a expression on MGT is still controversial, aberrant expression of sLe antigens is thought to be induced by malignant changes in the mammary gland cells, which show no sLe antigens expressed under normal conditions. Taken together, results from this study suggest that sLe antigens may be a marker of tumourigenesis in FMGT.

In vitro studies have shown that sLe antigens, which are expressed on tumour cells, play a critical role in adhesion to vascular endothelial cells.^14,28,29 This adhesion potential may relate to metastatic potential, which affects patient prognosis. Several clinical studies have been conducted to determine the relationship between tumour malignancy and the degree of sLe antigen expression in several tumours.^20,30,31 The results from these studies imply that these carbohydrate antigens play an important role in metastasis. In contrast to these findings, however, our study did not reveal any relationship between sLe antigen expression and clinicopathological features, including distant metastasis. In this study we performed cytological examinations to check the lymph node involvement in only cases with palpable lymphadenopathy. However, lymph node involvement is not always concurrent with swelling of nodes.⁵ Furthermore, we only evaluated distant metastasis by thoracic X-ray findings, and no post-mortem examination was performed. These factors may affect the results and were thought to be limitations of this study. In fact, no significant differences in survival were observed based on sLe antigen expression (Kaplan–Meier curves are not shown). Additionally, given the small number of patients included in this study, further studies with a large patient population will be necessary to clarify whether the sLe antigens have significant roles in tumour cell adhesion and metastatic potential or not.

In this study, serum sLe^x concentrations were measured to evaluate their potential as a tumour marker. Serum tumour markers can be helpful, non-invasive tools to diagnose tumours and provide information on the progression and recurrence of tumours.^21,32–34 Serum sLe^x concentrations were significantly different between mammary adenocarcinoma patients and patients with other diseases. In addition, serum sLe^x concentrations tended to be higher in mammary adenocarcinoma patients than normal cats, although the difference was not significant. These results suggest that serum sLe^x levels could serve as a negative predictive serum tumour marker for FMGT. However, studies with large populations are required to determine the usefulness and the cut-off value of the serum sLex concentration as a tumour marker of feline MGT. Some mammary adenocarcinoma patients showed extremely elevated levels of sLe^x and a considerably poor prognosis with carcinomatous pleuritis. However, a significant correlation between sLe^x expression level and prognosis was unclear in the longitudinal assessment of these cats. It is important to note that the number of FMGT patients in this study was small and continuous evaluation of serum sLe^x concentrations was not performed. Thus, further research is needed to determine the usefulness of sLe^x as a serum FMGT marker.

Conclusions

This study demonstrated that adenocarcinoma tissues from FMGT patients exhibited higher sLe antigen expression than benign and normal mammary tissues did. These results suggest that sLe antigens may be expressed following malignant transformation of FMGT, similar to human breast cancers and canine MGT. In addition, serum levels of sLe^x in patients with adenocarcinoma seemed to be higher than in those with benign FMGT and in normal cats. Although the relationship between their expression and FMGT patient prognosis remains to be elucidated, sLe antigen expression potentially correlates with malignancy and prognosis of FMGT, and may be a useful marker for FMGT. Further studies are needed to clarify the biological role of sLe antigens in FMGT and to confirm their usefulness in clinical practice.

Footnotes

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest

The authors do not have any potential conflicts of interest to declare.

Accepted: 12 August 2013

References

Dorn

Taylor

Frye

Hibbard

. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. I. Methodology and description of cases. J Natl Cancer Inst 1968; 40: 295–305.

Dorn

Taylor

Schneider

, et al. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda Country. J Natl Cancer Inst 1968; 40: 307–318.

Hayes

Milne

Mandell

. Epidemiological features of feline mammary carcinoma. Vet Rec 1981; 108: 476–479.

Lana

Rutteman

Withrow

. Tumors of the mammary gland. In: Withrow

Vail

(eds). Small animal clinical oncology. 4th edn. Toronto: Saunders Elsevier, 2001, pp 628–636.

Giménez

Hecht

Craig

Legendre

. Early detection, aggressive therapy: optimizing the management of feline mammary masses. J Feline Med Surg 2010; 12: 214–224.

Ito

Kadosawa

Mochizuki

, et al. Prognosis of malignant mammary tumor in 53 cats. J Vet Med Sci 1996; 58: 723–726.

Weijer

Hart

. Prognostic factors in feline mammary carcinoma. J Natl Cancer Inst 1983; 70: 709–716.

De Maria

Olivero

Iussich

, et al. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res 2005; 65: 907–912.

Millanta

Lazzeri

Vannozzi

, et al. Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas. Vet Pathol 2002; 39: 690–696.

10.

Islam

Matsumoto

Hidaka

, et al. Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis. Vet J 2012; 192: 338–344.

11.

Millanta

Citi

Della Santa

, et al. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers. Breast Cancer Res Treat 2006; 98: 115–120.

12.

Chambers

Groom

MacDonald

. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563–572.

13.

Madsen

Sahai

. Cancer dissemination – lessons from leukocytes. Dev Cell 2010; 19: 13–26.

14.

Takada

Ohmori

Yoneda

, et al. Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 1993; 53: 354–361.

15.

Kannagi

Izawa

Koike

, et al. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004; 95: 377–384.

16.

Hakomori

. Tumor malignancy defined by aberrant glycosylation and sphingo (glyco) lipid metabolism. Cancer Res 1996; 56: 5309–5318.

17.

Yusa

Miyazaki

Kimura

, et al. Epigenetic silencing of the sulfate transporter gene DTDST induces sialyl Lewisx expression and accelerates proliferation of colon cancer cells. Cancer Res 2010; 70: 4064–4073.

18.

Cazet

Julien

Bobowski

, et al. Consequences of the expression of sialylated antigens in breast cancer. Carbohydr Res 2010; 345: 1377–1383.

19.

Saldova

Royle

Radcliffe

, et al. Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 2007; 17: 1344–1356.

20.

Nakagoe

Fukushima

Itoyanagi

, et al. Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol 2002; 128: 257–264.

21.

Abd Hamid

Royle

Saldova

, et al. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 2008; 18: 1105–1118.

22.

Kannagi

. Carbohydrate antigen sialyl Lewis a – its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J 2007; 30: 189–209.

23.

Matsui

Kojima

Suzuki

, et al. Sialyl Lewis a expression as a predictor of the prognosis of colon carcinoma patients in a prospective randomized clinical trial. Jpn J Clin Oncol 2004; 34: 588–593.

24.

Nakagawa

Uyama

Ohashi

, et al. The expression of sialyl Lewis x in canine and feline mammary gland tumors. J Vet Med Sci 2002; 64: 949–952.

25.

Nowak

Madej

Dziegiel

, et al. Tumor-associated carbohydrate antigens: sialyl Lewis a, T/Tn antigens in canine mammary tumors. Vet Pathol 2009; 46: 222–226.

26.

Pinho

Matos

Lopes

, et al. Sialyl Lewis x expression in canine malignant mammary tumours correlation with clinicopathological features and E-Cadherin expression. BMC Cancer 2007; 7: 124.

27.

Renkonen

Paavonen

Renkonen

. Endothelial and epithelial expression of sialyl lewis^x and sialyl lewis^a in lesions of breast carcinoma. Int J Cancer 1997; 74: 296–300.

28.

Nakagawa

Endo

Watanabe

, et al. Adhesional function of canine mammary gland tumor cells expressing sialyl Lewis x. J Vet Med Sci 2009; 71: 1225–1228.

29.

Ugorski

Laskowska

. Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol 2002; 49: 303–311.

30.

Matsui

Kojima

Suzuki

, et al. Sialyl Lewis a expression as a predictor of the prognosis of colon carcinoma patients in a prospective randomized clinical trial. Jpn J Clin Oncol 2004; 34: 588–593.

31.

Saito

Fujii

Kawakami

, et al. Increased expression of sialyl-Lewis a correlates with poor survival in upper urinary tract urothelial cancer patients. Anticancer Res 2003; 23: 3441–3446.

32.

Fujita

Murayama

Hanamura

, et al. CSLEX (Sialyl Lewis x) is a useful tumor marker for monitoring of breast cancer patients. Jpn J Clin Oncol 2011; 41: 394–399.

33.

Hanski

Zimmer

, et al. Characterization of the major sialyl-Lex-positive mucins present in colon, colon carcinoma, and sera of patients with colorectal cancer. Cancer Res 1995; 55: 928–933.

34.